AKR7A2

Across TCGA pan-cancer cohorts, AKR7A2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated AKR7A2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher AKR7A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKR7A2 expression acts as an unfavorable survival marker.

LAML and UCEC are the cancer types where AKR7A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.082	0.582	.004	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

AKR7A2–LAML (DFS)

Open the LAML breakdown →